clinical trial · NCT06672185
ARC101 in Advanced Solid Tumors
Third Arc Bio·phase1·recruiting·n = 70
Advanced Solid TumorARC101
brief summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.
started
Feb 5, 2025
primary completion
May 1, 2028
completion
Aug 1, 2028
last updated
Apr 3, 2026
official title
A Phase 1 Study of ARC101 in Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol